MHRA authorisation of new treatment for chronic kidney disease associated with diabetes

March 9, 2022
Research and Development

The MHRA has authorised the use of Kerendia® (finerenone) (10mg or 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) …

Moderna announces its global public health strategy

March 8, 2022

Moderna has announced its global public health strategy through four new initiatives which aim to advance mRNA vaccines for the …

Study may see end of need for invasive endometriosis diagnosis surgery

March 8, 2022
Manufacturing and Production

A new study of women living with endometriosis is underway, exploring the potential of Artificial intelligence (AI), and cutting-edge medical …

Neuraxpharm expands in Southeast Europe

March 8, 2022
Manufacturing and Production

Neuraxpharm Group have announced the expansion of its business in Southeast Europe, through the acquisition of Brain Therapeutics, a company …

Major US study finds COVID-19 vaccines not linked to deaths

March 8, 2022
Manufacturing and Production

A study into vaccine side-effects, based in the US, has found no link between two COVID-19 jabs and the number …

Malaysia to receive Pfizer’s COVID-19 pills in two weeks, says Health Minister

March 7, 2022
Sales and Marketing

Khairy Jamaluddin, Health Minister of Malaysia, has shared that the country expects to receive its first shipment of Pfizer’s oral …

HUTCHMED receives $15 million to begin Phase III study of lung cancer treatment

March 7, 2022
Sales and Marketing

HUTCHMED has received $15 million from AstraZeneca, for the initiation of start-up activities for SAFFRON, the first global Phase III …

AbbVie acquires Syndesi Therapeutics

March 7, 2022
Sales and Marketing

Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …

India: approval for drug treating CKD-associated anaemia

March 7, 2022
Sales and Marketing

Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …

Phase III trial into nirsevimab for RSV treatment yields positive results

March 4, 2022
Medical Communications

The latest results from Sanofi and AstraZeneca’s Phase III trial nirsevimab support the vaccine’s ability to protect all infants from …

Median Technologies iBiopsy Lung Cancer Screening Software

March 4, 2022
Medical Communications

Median Technologies has announced that the company has filed a regulatory submission to the FDA for its iBiopsy Lung Cancer …

Promising treatment targeting 40% mortality Candida infection

March 4, 2022
Medical Communications

A Promising Innovation Medicine (PIM) designation has been awarded to rezafungin by the MHRA, for the treatment of invasive candidiasis. …

Anti-inflammatory baricitinib is a life-saving COVID-19 drug

March 4, 2022
Medical Communications

UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …

Risk of hospitalisation five times higher with J&J

March 3, 2022
Business Services, Medical Communications

A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …

FDA grants breakthrough therapy designation to RSV vaccine

March 3, 2022
Business Services, Medical Communications

The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …

WHO recommends Merck’s COVID-19 pill

March 3, 2022
Business Services, Medical Communications

WHO have recommended Merck’s pill, molnupiravir, for the treatment of COVID-19 in patients in high risk groups, such as the …

First smart connected insulin pens made available on NHS

March 2, 2022
Research and Development

Today, Novo Nordisk will launch the first smart connected insulin pens to be made available on NHS prescription. The pens, …

Fera Pharmaceuticals receives Orphan Drug Designation from FDA for sickle cell treatment

March 2, 2022
Research and Development

The FDA has granted an Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an …

HPV vaccines could mean only one smear test a lifetime

March 2, 2022
Research and Development

A leading scientist has said that women who have the HPV vaccine may need only one smear test to prevent …

FDA share new trial guidelines to further cancer therapy development

March 2, 2022
Research and Development

The FDA has issued three recommendations to industry for clinical trials, to support US President Joe Biden’s relaunch of the …

The Gateway to Local Adoption Series

Latest content